X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5583) 5583
Publication (702) 702
Book Review (114) 114
Book Chapter (73) 73
Book / eBook (25) 25
Conference Proceeding (12) 12
Dissertation (3) 3
Newsletter (3) 3
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3903) 3903
humans (2088) 2088
male (1856) 1856
index medicus (1636) 1636
rats (1560) 1560
cyclic amp - metabolism (1472) 1472
pharmacology & pharmacy (1237) 1237
phosphodiesterase inhibitors - pharmacology (1094) 1094
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (895) 895
mice (868) 868
female (796) 796
neurosciences (764) 764
biochemistry & molecular biology (758) 758
camp (729) 729
cells, cultured (698) 698
cyclic gmp - metabolism (697) 697
in vitro techniques (663) 663
dose-response relationship, drug (657) 657
cyclic amp (643) 643
cell biology (612) 612
phosphodiesterase (578) 578
signal transduction (576) 576
enzyme inhibitors - pharmacology (560) 560
cyclic nucleotide phosphodiesterases, type 4 (506) 506
cyclic-amp (497) 497
phosphorylation (493) 493
physiology (482) 482
rats, sprague-dawley (470) 470
nitric oxide (464) 464
3',5'-cyclic-amp phosphodiesterases - metabolism (413) 413
activation (413) 413
expression (402) 402
calcium - metabolism (397) 397
cyclic amp-dependent protein kinases - metabolism (389) 389
nitric-oxide (384) 384
cgmp (378) 378
signal transduction - drug effects (375) 375
kinetics (366) 366
colforsin - pharmacology (365) 365
proteins (344) 344
cyclic amp - physiology (343) 343
rats, wistar (343) 343
dependent protein-kinase (342) 342
adenylyl cyclases - metabolism (335) 335
rolipram (332) 332
calcium (327) 327
phosphodiesterase inhibitors - therapeutic use (317) 317
analysis (316) 316
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (314) 314
cells (313) 313
article (304) 304
cyclic gmp (304) 304
signal transduction - physiology (302) 302
1-methyl-3-isobutylxanthine - pharmacology (301) 301
inhibition (298) 298
cell line (292) 292
cyclic nucleotide phosphodiesterases, type 5 (288) 288
physiological aspects (283) 283
time factors (281) 281
cyclic adenylic acid (279) 279
endocrinology & metabolism (271) 271
nitric oxide - metabolism (267) 267
cyclic amp - pharmacology (264) 264
sildenafil citrate (263) 263
kinases (261) 261
research (261) 261
in-vitro (260) 260
cyclic-nucleotide phosphodiesterases (258) 258
cyclic nucleotide phosphodiesterases, type 3 (248) 248
phosphoric diester hydrolases - metabolism (247) 247
receptors (242) 242
structure-activity relationship (240) 240
guinea pigs (238) 238
isoproterenol - pharmacology (236) 236
sildenafil (235) 235
chemistry, medicinal (230) 230
piperazines - pharmacology (221) 221
gene expression (220) 220
rodents (219) 219
cyclic gmp - pharmacology (218) 218
nitric-oxide synthase (217) 217
cyclic amp-dependent protein kinases - antagonists & inhibitors (213) 213
cyclic-nucleotide phosphodiesterase (213) 213
rolipram - pharmacology (212) 212
cyclic-gmp (211) 211
enzymes (210) 210
disease models, animal (208) 208
mice, inbred c57bl (207) 207
adult (206) 206
adenosine (204) 204
cardiac & cardiovascular systems (204) 204
protein kinases (201) 201
rat (200) 200
rabbits (199) 199
receptor (198) 198
brain (197) 197
protein-kinase (194) 194
adenylate-cyclase (193) 193
phosphodiesterase inhibitors (193) 193
isoenzymes - antagonists & inhibitors (191) 191
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
UofT at Mississauga - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Periodical Stacks (1) 1
Online Resources - Online (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation Research, ISSN 0009-7330, 03/2015, Volume 116, Issue 7, pp. 1120 - 1132
RATIONALE:Neointimal hyperplasia characterized by abnormal accumulation of vascular smooth muscle cells (SMCs) is a hallmark of occlusive disorders such as... 
Smooth muscle cell | Cyclic nucleotide phosphodiesterases, type 1C | Neointima formation | neointima formation | CARDIAC & CARDIOVASCULAR SYSTEMS | smooth muscle cell | TYROSINE PHOSPHORYLATION | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | DEPENDENT PROTEIN-KINASE | cyclic nucleotide phosphodiesterases, type 1C | CORONARY-ARTERY | ELUTING STENTS | CORECEPTOR FUNCTION | MEDIATED ENDOCYTOSIS | MOUSE MODEL | BETA PDGFR-BETA | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | MACROPHAGE DIFFERENTIATION | Humans | Male | Lysosomes - physiology | Cyclic AMP - physiology | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | RNA Interference | Proteolysis | Cell Division | Neointima - enzymology | Models, Animal | Protein Stability | Myocytes, Smooth Muscle - cytology | Cyclic Nucleotide Phosphodiesterases, Type 1 - physiology | Carotid Artery Injuries - pathology | Receptor, Platelet-Derived Growth Factor beta - metabolism | Myocytes, Smooth Muscle - enzymology | Mice, Inbred C57BL | Cells, Cultured | Enzyme Induction | Low Density Lipoprotein Receptor-Related Protein-1 - metabolism | Rats | Muscle, Smooth, Vascular - cytology | Rats, Sprague-Dawley | Endocytosis - physiology | Mice, Knockout | Protein Interaction Mapping | Neointima - physiopathology | Cyclic Nucleotide Phosphodiesterases, Type 1 - deficiency | Animals | Carotid Artery Injuries - enzymology | Signal Transduction - physiology | Mice | Cell Movement | smooth muscle cells | phosphodiesterase | cyclic nucleotide | and neointimal hyperplasia
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 12/2012, Volume 123, Issue 6, pp. 1019 - 1029
Traumatic brain injury (TBI) results in significant inflammation which contributes to the evolving pathology. Previously, we have demonstrated that cyclic AMP... 
traumatic brain injury | phosphodiesterase | cAMP | fluid‐percussion | inflammation | isoform | fluid-percussion | FUNCTIONAL RECOVERY | LOCALIZATION | DIFFERENTIAL EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | SPLICE VARIANTS | NEUROSCIENCES | PDE4 INHIBITORS | ROLIPRAM | RAT-BRAIN | TNF-ALPHA | CAMP-SPECIFIC PHOSPHODIESTERASES | Cyclic Nucleotide Phosphodiesterases, Type 3 - genetics | Phosphoric Diester Hydrolases - biosynthesis | Male | Cyclic Nucleotide Phosphodiesterases, Type 1 - biosynthesis | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Phosphorylation - genetics | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - biosynthesis | Disease Models, Animal | Phosphoric Diester Hydrolases - metabolism | Isoenzymes - genetics | Brain Injuries - enzymology | Rats | Phosphoric Diester Hydrolases - genetics | Brain Injuries - genetics | Brain Injuries - therapy | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Rats, Sprague-Dawley | Cyclic Nucleotide Phosphodiesterases, Type 3 - biosynthesis | Cyclic AMP - antagonists & inhibitors | Animals | Cyclic AMP - biosynthesis | Gene Expression Regulation, Enzymologic - genetics | Isoenzymes - biosynthesis | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Isoenzymes - antagonists & inhibitors | Brain | Neurons | Analysis | Injuries | Neurochemistry | Enzymes | Brain damage | Gene expression | Trauma | Ca super(2+)/calmodulin-dependent phosphodiesterase | Phosphorylation | Traumatic brain injury | Cortex (parietal) | Cyclic AMP | Inflammation | Glia | Western blotting
Journal Article
Clinical Science, ISSN 0143-5221, 12/2015, Volume 129, Issue 12, pp. 1061 - 1075
Reduced nitric oxide (NO)/cGMP signalling is observed in age-related vascular disease. We hypothesize that this disturbed signalling involves effects of... 
genetic association | phosphodiesterases | blood pressure | aging | vascular disease | Vascular disease | Aging | Blood pressure | Genetic association | Phosphodiesterases | MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE-STRESS | ENDOTHELIAL DYSFUNCTION | ATHEROSCLEROSIS | BLOOD-PRESSURE | ARTERIAL | DISEASE | NITRIC-OXIDE | VINPOCETINE | CONGESTIVE-HEART-FAILURE | ASSOCIATION | Blood Pressure | Endonucleases - deficiency | Endonucleases - genetics | Humans | Hyperplasia | Gene Expression Regulation, Neoplastic | DNA-Binding Proteins - deficiency | Dose-Response Relationship, Drug | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Aging - genetics | Carotid Artery Diseases - pathology | Cellular Senescence | Carotid Arteries - enzymology | Hypertension - enzymology | Hypertension - genetics | Myocytes, Smooth Muscle - drug effects | Phosphodiesterase 5 Inhibitors - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Second Messenger Systems | Muscle, Smooth, Vascular - drug effects | Genetic Predisposition to Disease | Genome-Wide Association Study | Vasodilator Agents - pharmacology | Carotid Intima-Media Thickness | Myocytes, Smooth Muscle - enzymology | Mice, Inbred C57BL | Cells, Cultured | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | DNA-Binding Proteins - genetics | Hypertension - physiopathology | Mice, Knockout | Hydrolysis | Phenotype | Animals | Cyclic GMP - metabolism | Carotid Artery Diseases - enzymology | Carotid Artery Diseases - genetics | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Carotid Arteries - pathology | Polymorphism, Single Nucleotide | Vasodilation - drug effects | In Vitro Techniques | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Muscle, Smooth, Vascular - enzymology | Aging - metabolism
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2016, Volume 59, Issue 3, pp. 1149 - 1164
Journal Article
Molecular Nutrition & Food Research, ISSN 1613-4125, 11/2011, Volume 55, Issue 11, pp. 1677 - 1689
Scope: Curcumin inhibits proliferation of many cancer cells. Cyclic nucleotide phosphodiesterases (PDEs), by hydrolyzing intracellular cyclic... 
DNMT1 | Rolipram | Nimodipine | cAMP/cGMP | Cancer | CAMP/cGMP | CANCER-CELLS | APOPTOSIS | HEMI-METHYLATED DNA | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | FOOD SCIENCE & TECHNOLOGY | DOWN-REGULATION | VASCULAR SMOOTH-MUSCLE | ARREST | SRA DOMAIN | ENDOTHELIAL-CELLS | GENE-EXPRESSION | Neoplasm Proteins - antagonists & inhibitors | Cyclin-Dependent Kinase Inhibitor Proteins - metabolism | Molecular Targeted Therapy | Neoplasm Proteins - metabolism | RNA, Messenger - metabolism | DNA (Cytosine-5-)-Methyltransferases - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Isoenzymes - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Melanoma - metabolism | Recombinant Proteins - metabolism | Cell Survival - drug effects | DNA (Cytosine-5-)-Methyltransferase 1 | Isoenzymes - genetics | Curcumin - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Nuclear Proteins - metabolism | Animals | Cyclic GMP - metabolism | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Isoenzymes - antagonists & inhibitors | Cell proliferation | Ca super(2+)/calmodulin-dependent phosphodiesterase | 3',5'-Cyclic-nucleotide phosphodiesterase | DNMT1 protein | Melanoma | Cyclic AMP | epigenetics | Signal transduction | Cyclic GMP | Cyclin A | Cell cycle | Cyclin-dependent kinase inhibitor p27 | DNA methyltransferase | Curcumin | phosphodiesterase | cyclin-dependent kinase inhibitors | Food | Life Sciences | Cellular Biology | Biochemistry, Molecular Biology
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 08/2017, Volume 174, Issue 15, pp. 2563 - 2575
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 11/2017, Volume 174, Issue 22, pp. 4186 - 4198
Journal Article
Psychopharmacology, ISSN 0033-3158, 09/2016, Volume 233, Issue 17, pp. 3113 - 3124
Therapeutic agents for memory enhancement in psychiatric disorders, such as schizophrenia, are urgently needed.The aim of this study is to characterize the... 
Phosphodiesterase-1 | Cyclic AMP | Novel object recognition | Cyclic GMP | Memory | Conditioned avoidance response | Neurosciences | Biomedicine | Pharmacology/Toxicology | Psychiatry | LONG-TERM-MEMORY | OBJECT RECOGNITION MEMORY | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | PSYCHIATRY | COGNITIVE IMPAIRMENT | TANDEM MASS-SPECTROMETRY | NEUROSCIENCES | ANTIPSYCHOTIC-DRUGS | PHARMACOLOGY & PHARMACY | MOLECULAR-CLONING | DOPAMINE D-1 | CONDITIONED AVOIDANCE-RESPONSE | WORKING-MEMORY | Memory - drug effects | Risperidone - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Rats | Schizophrenia | Male | Schizophrenic Psychology | Heterocyclic Compounds, 4 or More Rings - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Animals | Drug Interactions | Recognition (Psychology) - drug effects | Exploratory Behavior - drug effects | Antipsychotic Agents - pharmacology | Nootropic Agents - pharmacology | Enzyme inhibitors | Patient outcomes | Dosage and administration | Phosphodiesterases | Health aspects | Enzymes | Neuropsychology | Rodents | Animal memory | Psychopharmacology | Original Investigation | Pharmaceutical Sciences | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Farmaceutiska vetenskaper | Pharmacology | Farmakologi | Medicinska och farmaceutiska grundvetenskaper | Farmakologi och toxikologi | Pharmacology and Toxicology
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2012, Volume 7, Issue 10, p. e47826
Background: We investigated the role of cyclic nucleotide phosphodiesterases (PDEs) in the spatiotemporal control of intracellular cAMP concentrations in rat... 
SELECTIVE INHIBITOR | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | ADENYLYL-CYCLASE | MULTIDISCIPLINARY SCIENCES | CARDIAC MYOCYTES | NITRIC-OXIDE | CGMP | DEPENDENT PROTEIN-KINASE | PROLIFERATION | CARDIOVASCULAR TISSUES | EXPRESSION | Aorta - metabolism | Adrenergic beta-Antagonists - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Time Factors | Fluorescence Resonance Energy Transfer | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Myocytes, Smooth Muscle - drug effects | Cyclic AMP - metabolism | Myocytes, Smooth Muscle - cytology | Cell Membrane - drug effects | Muscle, Smooth, Vascular - drug effects | Myocytes, Smooth Muscle - enzymology | Aorta - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism | Adrenergic beta-Agonists - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Rats | Muscle, Smooth, Vascular - cytology | Cell Membrane - enzymology | Animals | Signal Transduction - drug effects | Isoproterenol - pharmacology | Signal Transduction - physiology | Aorta - cytology | Primary Cell Culture | Muscle, Smooth, Vascular - enzymology | Laboratories | Fluorescence | Smooth muscle | Antagonists | Isoproterenol | Kinases | Recovery | Experiments | Proteins | Dynamic control | Rodents | Aorta | Physiology | Inhibition | Fluorescence resonance energy transfer | Localization | Phosphodiesterase | 3',5'-Cyclic-nucleotide phosphodiesterase | Muscles | Cyclic AMP | Biophysics | Gene expression | Endothelium | Studies | Inhibitors | Coronary vessels | Nitric oxide | Adrenergic receptors | Kinetics | Intracellular | Energy transfer
Journal Article
Toxicology Letters, ISSN 0378-4274, 10/2016, Volume 260, pp. 18 - 27
The heavy metal cadmium is a widespread environmental contaminant that has gained public attention due to the global increase in cadmium-containing electronic... 
Osteoblast | Cadmium | Calmodulin | Apoptosis | ACTIVATED PROTEIN-KINASE | INDUCED APOPTOSIS | CYCLE ARREST | ERK ACTIVATION | E-WASTE | IN-VITRO | GENE-EXPRESSION | TOXICOLOGY | INHIBITOR | EXPOSURE | Calmodulin - agonists | Apoptosis - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - chemistry | Humans | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Environmental Pollutants - antagonists & inhibitors | Environmental Pollutants - toxicity | Cadmium - agonists | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism | Biomarkers - metabolism | Calmodulin - metabolism | Cadmium - toxicity | Osteoblasts - enzymology | Osteoblasts - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Lethal Dose 50 | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - antagonists & inhibitors | Calcium-Calmodulin-Dependent Protein Kinase Kinase - chemistry | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - chemistry | MAP Kinase Signaling System - drug effects | Naphthalimides - pharmacology | Calcium Signaling - drug effects | Calcium-Calmodulin-Dependent Protein Kinase Kinase - antagonists & inhibitors | Calcium-Calmodulin-Dependent Protein Kinase Kinase - metabolism | Cell Line, Tumor | Benzimidazoles - pharmacology | Protein Kinase Inhibitors - pharmacology | Osteoblasts - metabolism | Benzylamines - pharmacology | Calmodulin - antagonists & inhibitors | Cadmium - chemistry | Environmental Pollutants - agonists | Index Medicus | Biomedical materials | Inhibitors | Pathways | Toxicity | Activation | Kinases
Journal Article